These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M; Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896 [TBL] [Abstract][Full Text] [Related]
4. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695 [TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936 [TBL] [Abstract][Full Text] [Related]
6. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195 [TBL] [Abstract][Full Text] [Related]
7. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. Ko TM; Chung WH; Wei CY; Shih HY; Chen JK; Lin CH; Chen YT; Hung SI J Allergy Clin Immunol; 2011 Dec; 128(6):1266-1276.e11. PubMed ID: 21924464 [TBL] [Abstract][Full Text] [Related]
8. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Guillaume JC; Roujeau JC; Revuz J; Penso D; Touraine R Arch Dermatol; 1987 Sep; 123(9):1166-70. PubMed ID: 3632001 [TBL] [Abstract][Full Text] [Related]
9. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. Murata J; Abe R; Shimizu H J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887 [TBL] [Abstract][Full Text] [Related]
10. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164 [TBL] [Abstract][Full Text] [Related]
11. [Stevens-Johnson syndrome and toxic epidermal necrolysis following intake of sulfonamides]. Aberer W; Stingl G; Wolff K Hautarzt; 1982 Sep; 33(9):484-90. PubMed ID: 7174320 [TBL] [Abstract][Full Text] [Related]